Intravitreal Ranibizumab for Subfoveal Choroidal Neovascularization from Age-Related Macular Degeneration with Combined Severe Diabetic Retinopathy
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Han, So Young | - |
dc.contributor.author | Bae, Jeong Hun | - |
dc.contributor.author | Oh, Jaeryung | - |
dc.contributor.author | Yu, Hyeong Gon | - |
dc.contributor.author | Song, Su Jeong | - |
dc.date.accessioned | 2021-09-04T19:40:33Z | - |
dc.date.available | 2021-09-04T19:40:33Z | - |
dc.date.created | 2021-06-15 | - |
dc.date.issued | 2015-02 | - |
dc.identifier.issn | 2233-6079 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/94537 | - |
dc.description.abstract | Background: To evaluate the efficacy of intravitreal ranibizumab for subfoveal choroidal neovascularization (CNV) from agerelated macular degeneration (AMD) with combined severe diabetic retinopathy (DR). Methods: This retrospective, interventional case series included eleven patients (mean age, 70.09 years; range, 54 to 83 years) with at least severe non-proliferative DR and subfoveal CNV secondary to AMD. Each subject was treated with intravitreal injections of 0.5 mg ranibizumab. The primary outcomes included change in best-corrected visual acuity and central subfield thickness (CST) on optical coherence tomography (OCT). Results: The mean follow-up time was 16.7 +/- 14 months (range, 6 to 31 months). Mean visual acuity improved from 1.21 +/- 0.80 logarithm of the minimum angle of resolution (logMAR) to 1.0 +/- 0.6 logMAR (P=0.107), 0.95 +/- 0.62 logMAR (P=0.044), 1.10 +/- 0.68 logMAR (P=0.296), and 1.13 +/- 0.66 logMAR (P=0.838) at 1, 3, 6, and 12 months after injection, respectively. Eight patients (72.7%) gained or maintained vision (mean 0.32 logMAR), whereas three patients (27.3%) lost more than one line of vision (mean 0.51 logMAR). The mean OCT CST was 343.9 +/- 134.6 mu m at baseline, and the mean CST at 1, 3, 6, 12 months after the injection was 367.8 +/- 172.1 (P=0.864), 346.2 +/- 246.2 (P=0.857), 342 +/- 194.1 (P=0.551), and 294.2 +/- 108.3 mu m (P=0.621), respectively. Conclusion: Intravitreal ranibizumab injection can be considered to be a therapy for the stabilization of subfoveal CNV secondary to AMD with combined severe DR. However, these patients might exhibit limited visual improvement after treatment. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | KOREAN DIABETES ASSOC | - |
dc.subject | ENDOTHELIAL GROWTH-FACTOR | - |
dc.subject | PHOTODYNAMIC THERAPY | - |
dc.subject | VISUAL IMPAIRMENT | - |
dc.subject | VERTEPORFIN | - |
dc.subject | PREVALENCE | - |
dc.title | Intravitreal Ranibizumab for Subfoveal Choroidal Neovascularization from Age-Related Macular Degeneration with Combined Severe Diabetic Retinopathy | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Oh, Jaeryung | - |
dc.identifier.doi | 10.4093/dmj.2015.39.1.46 | - |
dc.identifier.scopusid | 2-s2.0-84923229249 | - |
dc.identifier.wosid | 000368000300007 | - |
dc.identifier.bibliographicCitation | DIABETES & METABOLISM JOURNAL, v.39, no.1, pp.46 - 50 | - |
dc.relation.isPartOf | DIABETES & METABOLISM JOURNAL | - |
dc.citation.title | DIABETES & METABOLISM JOURNAL | - |
dc.citation.volume | 39 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 46 | - |
dc.citation.endPage | 50 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART001962042 | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | Endocrinology & Metabolism | - |
dc.relation.journalWebOfScienceCategory | Endocrinology & Metabolism | - |
dc.subject.keywordPlus | ENDOTHELIAL GROWTH-FACTOR | - |
dc.subject.keywordPlus | PHOTODYNAMIC THERAPY | - |
dc.subject.keywordPlus | VISUAL IMPAIRMENT | - |
dc.subject.keywordPlus | VERTEPORFIN | - |
dc.subject.keywordPlus | PREVALENCE | - |
dc.subject.keywordAuthor | Choroidal neovascularization | - |
dc.subject.keywordAuthor | Diabetic retinopathy | - |
dc.subject.keywordAuthor | Macular degeneration | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.